Table 2 Univariate and multivariate analysis of overall survival and disease-free survival in the whole cohort

Age (years)

1.00 (0.99–1.01)

0.818

1.00 (0.99–1.01)

0.852

Sex (Male vs Female)

0.95 (0.77–1.16)

0.611

0.99 (0.84–1.18)

0.950

HBV infection (Yes vs No)

1.01 (0.80–1.28)

0.908

1.13 (0.93–1.38)

0.208

Cirrhosis (Yes vs No)

0.95 (0.81–1.11)

0.498

1.08 (0.95–1.24)

0.237

TBil (μmol/L)

1.02 (1.01–1.03)

0.003

1.01 (1.00–1.02)

0.087

1.01 (1.00–1.02)

0.010

1.01 (1.00–1.02)

0.186

Child-pugh (B vs A)

2.04 (1.54–2.70)

< 0.001

1.27 (0.93–1.72)

0.131

1.72 (1.34–2.20)

< 0.001

1.13 (0.86–1.49)

0.371

AFP (> 400 vs 400 ng/mL)

1.66 (1.43–1.94)

< 0.001

1.43 (1.22–1.67)

< 0.001

1.35 (1.19–1.54)

< 0.001

1.22 (1.07–1.40)

0.004

γ-GT (> 54 vs ≤54 U/L)

1.76 (1.51–2.05)

< 0.001

1.38 (1.17–1.62)

< 0.001

1.69 (1.49–1.92)

< 0.001

1.42 (1.24–1.63)

< 0.001

Transfusion (Yes vs No)

2.01 (1.54–2.61)

< 0.001

0.89 (0.66–1.22)

0.479

1.97 (1.57–2.48)

< 0.001

1.12 (0.86–1.46)

0.391

Tumor number (Multiple vs Single)

1.83 (1.54–2.17)

< 0.001

1.50 (1.23–1.82)

< 0.001

1.82 (1.58–2.10)

< 0.001

1.53 (1.29–1.80)

< 0.001

Tumor diameter (cm)

1.11 (1.09–1.13)

< 0.001

1.07 (1.05–1.09)

< 0.001

1.08 (1.06–1.09)

< 0.001

1.04 (1.02–1.06)

< 0.001

ES grading (III/IV vs I/II)

1.80 (1.34–2.42)

< 0.001

1.28 (0.95–1.74)

0.108

1.42 (1.13–1.78)

0.003

1.08 (0.85–1.37)

0.528

Capsule (Absent vs Present)

1.42 (1.20–1.70)

< 0.001

1.35 (1.12–1.62)

0.001

1.26 (1.09–1.47)

0.002

1.16 (0.99–1.35)

0.064

Satellite (Yes vs No)

1.51 (1.30–1.75)

< 0.001

0.98 (0.81–1.18)

0.812

1.46 (1.29–1.66)

< 0.001

1.05 (0.90–1.22)

0.527

MVI (Absent vs Present)

1.92 (1.65–2.23)

< 0.001

1.51 (1.27–1.79)

< 0.001

1.68 (1.48–1.90)

< 0.001

1.40 (1.22–1.62)

< 0.001

PA-TACE (Yes vs No)

0.89 (0.75–1.05)

0.165

0.93 (0.81–1.06)

0.280